NewsRoom Articles - Page 161 of 221

FridayJun 25, 2021 2:17 pm

RYAH Group Inc. (CSE: RYAH) Cannabis Clinical Trials Improve Due to Dose-Measuring Devices

Cannabis is a chemically variable plant making its clinical trials problematic, before the creation of dose-measuring devices RYAH Smart inhalers being used in one of the largest clinical studies of its kind focused on chronic pain Restrictive funding and legislative barriers regarding cannabis are rapidly dissipating Regulating dose size in cannabis clinical trials has proven problematic from one test subject to another because cannabis is a chemically variable plant. RYAH Group (CSE: RYAH), a health care analytics and technology company, has created IoT dose-measuring devices backed by powerful data analytics, allowing for more control for variables within a clinical setting. …

FridayJun 25, 2021 12:10 pm

Vivos Therapeutics Inc. (NASDAQ: VVOS) Founder and Chief Medical Officer Shares Company’s Groundbreaking Work in New Book

Dr. Dave Singh, Vivos Therapeutics Inc. founder and Chief Medical Officer, releases his new book titled Pneumopedics and Craniofacial Epigenetics The book is the product of Dr. Singh’s years of research and is a chronology of Vivo Therapeutics’ strides in innovation The book mainly covers craniofacial growth and developmental Genetics It also highlights the relationship between dentofacial anomalies and developmental deficiencies associated with downstream conditions such as Obstructive Sleep Apnea (“OSA”) Since its inception, Vivos Therapeutics (NASDAQ: VVOS) has been a trailblazer in diagnosing and treating mild-to-moderate Obstructive Sleep Apnea (“OSA”). Its main product — Vivos System — results from…

FridayJun 25, 2021 11:43 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Discusses Its Vision for Addressing Patient Needs

In 2021, Tryp Therapeutics plans on expanding its academic collaborations It also plans to initiate Phase 2a clinical studies for its synthetic psilocybin drug product as a way to determine efficacy in patient populations Tryp Therapeutics is constantly working on identifying alternative and better ways to control doses and control the patient experience in their dissociative state, mainly through innovations in drug formulation and delivery A primary objective of the administration of psilocybin is to increase the neuroplasticity of the brain Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) recently shed light on its operations and the vision that it has both…

ThursdayJun 24, 2021 3:18 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Targets Anxiety Disorders in Focus of Proprietary Psychedelic Treatments

Decision represents opportunity to help millions suffering from social, generalized anxiety disorders Global markets will reach an estimated $4 billion this year, with significant growth projected looking forward WHO estimates that 1 in 13 adults globally suffer from anxiety; treatment options have slow onset, undesirable side effects Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has identified social anxiety disorder, or SAD, and generalized anxiety disorder, or GAD, as the initial target indications for its proprietary psychedelic molecule CYB004 (https://ibn.fm/BQdjY). Collectively, the two global markets will reach an estimated $4 billion this year, with significant…

ThursdayJun 24, 2021 2:16 pm

Three Predictive Oncology Inc. (NASDAQ: POAI) Companies Participate in Popular Biotechnology Innovation Organization Digital Conference

More than 3,200 pharmaceutical and biotech companies, plus government and academic organizations attended latest BIO Conference Predictive Oncology’s Helomics, TumorGenesis, Soluble Biotech all attended the virtual conference from June 14-18, 2021 Companies leveraged different components of the conference to entertain new partnerships or customers Every industry has a revolving calendar of events, but some are “must attends” due to their global reach and prospective deal flow, like conferences put on by Biotechnology Innovation Organization, or just “BIO” as it’s known. This year, three wholly owned subsidiaries of Predictive Oncology (NASDAQ: POAI) – Helomics, TumorGenesis and Soluble Biotech – attended BIO…

WednesdayJun 23, 2021 2:51 pm

Brain Scientific Inc. (BRSF) to Remain at the Forefront of Innovative Brain Diagnostics as the Sector Grows Across New Applications

As a leading innovator in brain diagnostics technology, BRSF appears well placed to spot and predict driving forces behind the industry's expected rapid growth BRSF's Marketing Director was featured in an article giving prediction about key trends driving brain monitoring space in 2021 BRSF poised to remain at EEG forefront as exciting new opportunities lay ahead for this growing sector Recognized as a leading innovative player in the brain monitoring space, Brain Scientific (OTCQB: BRSF) continues to be at the forefront of what is next in neurology technology. The Company's Marketing Director, Irina Nazarova, was featured in Tech Times, a…

TuesdayJun 22, 2021 3:00 pm

Customized Brain Maps Help Boost Cancer, Epilepsy Treatments Outcomes

A team of medical device developers, neuroscientists, surgeons and engineers from the University of California San Diego is working on developing better customized maps that will be useful to physicians during brain tumor removal surgery. Maps do already exist that physicians can reference. However, one individual’s brain isn’t the same as another’s, which is why customized maps are needed. Additionally, an individual’s brain may sometimes reorganize itself as a response to damage caused by things such as growing tumors, which can make it even harder to remove the tumor. This is where sensors enter the picture. Surgical teams can utilize…

TuesdayJun 22, 2021 11:23 am

Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Partners with Cellevate for New Approach to Ovarian Cancer

Collaboration will use TumorGenesis’ expertise in cancer cell culture growth media in combination with Cellevate’s specialty in emerging field of nanofiber matrixes. Cutting-edge technology can help avoid mistakes in $2.6 billion process of bringing new drugs through FDA process. Coupling companies’ technology will give researchers ability to grow ovarian cancer tissues in 3D matrix support system with right media for right ovarian cancer cell types Getting a drug through the complete FDA process, from pre-clinical to approval, is an arduous and expensive task, although there are signs that approval rates are accelerating after years of decline. Companion diagnostics, new approaches…

MondayJun 21, 2021 2:05 pm

Analysis Uncovers Kidney Cancer Development, Response to Treatment

Researchers from the Rogel Cancer Center at the University of Michigan have sequenced the RNA of single cells in cancerous and benign kidney tumors. Using that information, they have determined cells from which various subtypes originate and how the tumor micro-environment affects the development of cancer and an individual’s response to treatment. The researchers’ discoveries were reported in “Proceedings of the National Academy of Sciences” journal and will be useful in helping better understand what impacts renal cell carcinoma and in assisting oncologists in choosing the best treatment for each patient. This, in turn, will be beneficial to patients, given…

MondayJun 21, 2021 12:10 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Gains Inclusion on Russell 2000 Index as Brain Cancer Trial Enrollment Advances

Brain cancer drug developer CNS Pharmaceuticals is actively enrolling patients for a potentially pivotal Phase 2 trial of the company’s lead drug candidate, Berubicin, a promising candidate for treating a devastating condition CNS’s focus has been on developing a means of combating glioblastoma, a fatal, generally incurable class of brain cancers that are aggressive and recurrent amid current surgical and chemotherapy interventions One patient from the Phase 1 trial of Berubicin 15 years ago remains cancer-free, as assessed in November, despite glioblastoma’s reputation for proving fatal generally within about 15 months of diagnosis CNS recently announced it will be included…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

RYAH Group Inc. (CSE: RYAH) Cannabis Clinical Trials Improve Due to Dose-Measuring Devices

Vivos Therapeutics Inc. (NASDAQ: VVOS) Founder and Chief Medical Officer Shares Company’s Groundbreaking Work in New Book

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Discusses Its Vision for Addressing Patient Needs

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Targets Anxiety Disorders in Focus of Proprietary Psychedelic Treatments

Three Predictive Oncology Inc. (NASDAQ: POAI) Companies Participate in Popular Biotechnology Innovation Organization Digital Conference

Brain Scientific Inc. (BRSF) to Remain at the Forefront of Innovative Brain Diagnostics as the Sector Grows Across New Applications

Customized Brain Maps Help Boost Cancer, Epilepsy Treatments Outcomes

Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Partners with Cellevate for New Approach to Ovarian Cancer

Analysis Uncovers Kidney Cancer Development, Response to Treatment

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Gains Inclusion on Russell 2000 Index as Brain Cancer Trial Enrollment Advances

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search